在危急的COVID-19患者中,铁和热的特征
Cédric Peleman1,2, Samya Van Coillie3,4, Symen Ligthart1,5
1Laboratory of Experimental Medicine and Paediatrics, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium.
Cell death and differentiation
|August 15, 2023
概括
危急的COVID-19患者表现出不同的细胞死亡概况. 识别这些特征,如热和肺细胞细胞死亡,可以实现个性化治疗策略,以获得更好的ICU结果.
科学领域:
- 关键护理医学 关键护理医学
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
背景情况:
- 在ICU中的危急COVID-19患者通常会由于广泛的细胞死亡而经历多个器官功能障碍.
- 铁和热是关键的受调细胞死亡途径,涉及COVID-19病原体,并代表潜在的治疗点.
研究的目的:
- 在危急的COVID-19患者中调查铁,铁,铁和肺细胞死亡的系统标志物.
- 根据这些细胞死亡生物标志物概况及其与临床结果的关联,确定不同的患者子组.
主要方法:
- 120名危急COVID-19患者的前性队列研究,在ICU入院后的前三天监测生物标志物.
- 与术后ICU患者和健康对照进行比较.
- 无监督集群用于根据生物标志物配置文件识别患者子组.
主要成果:
- 烧死标志物IL-18与高肺细胞死亡与增加机械通风需求相关.
- 高IL-1β (低肺细胞死亡) 与减少通风需求和死亡率有关.
- 铁消热和铁的标志物通常没有结果关联,除了高催化铁与降低生存率相关.
- 对于高级糖化终产品和与不良结果相关的GDF-15水平的可溶性受体.
结论:
- 危急的COVID-19患者呈现异质的全身细胞死亡特征.
- 通过热,铁和肺细胞细胞死亡标记物识别的不同亚组具有不同的临床结果.
- 生物标志物分析可能有助于为危急的COVID-19患者提供个性化治疗策略.
更多相关视频
08:05Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
14.2K
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
1.0K
相关概念视频
COPD: Pathogenesis and Clinical Features
344
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
344
Acute Respiratory Failure-II
272
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
272
Acute Respiratory Failure-I
245
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
245
Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
Acute Respiratory Failure-V
163
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
163
Acute Respiratory Failure-III
223
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
223
